Literature DB >> 12111656

[Prevalence of asymptommatic coeliac disease in children and adults in the Dresden region of Germany].

J Henker1, A Lösel, K Conrad, Th Hirsch, W Leupold.   

Abstract

BACKGROUND AND
OBJECTIVE: Coeliac disease (CD) can be present without any, only a few, or many symptoms. Since asymptomatic CD can have the same complications and also carries the same risk for malignant disease as clinically typical CD inadequately treated by diet, early diagnosis is essential. The prevalence of asymptomatic CD in the Dresden region was determined by antibody screening. At the same time the sensitivity and specificity of the different antibodies were calculated.
MATERIAL AND METHODS: Anti-gliadin and endomysium antibodies and total IgA content were measured in the serum of 3004 children (group A), aged 5-12 years, and of 4313 blood donors (group B), aged 17-64 years. Small-intestine biopsies were recommended if either (1) endomysium antibodies (EmA) or (2) anti-gliadin antibodies (ACA) and clinical symptoms or (3) AGA-IgG in the presence of total IgA deficiency and clinical symptoms had been demonstrated.
RESULTS: EmA were demonstrated in 0.17% of group A and in 0.28% of group B. But AGA were found much more frequently (group A: 3.89%, group B: 3.76%). The number of cases of CD confirmed by biopsy indicated a prevalence of asymptomatic CD of 1 in 500 children and 1 in 540 adults. Sensitivity and specificity of EmA were significantly higher than those of AGA.
CONCLUSION: Compared with a previous study on the prevalence of clinically typical CD in the same region, the present investigation indicates a four-fold higher prevalence of asymptomatic CD. Coeliac-specific antibodies should, therefore, be measured much more widely in the presence of certain symptoms and risk factors. While in adults the measurement of EmA is sufficient to provide the indication for a small-intestine biopsy, both EmA and AGA should be determined before a biopsy is undertaken in children.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111656     DOI: 10.1055/s-2002-32757

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  8 in total

Review 1.  The diagnosis and treatment of celiac disease.

Authors:  Detlef Schuppan; Klaus-Peter Zimmer
Journal:  Dtsch Arztebl Int       Date:  2013-12-06       Impact factor: 5.594

Review 2.  The spectrum of celiac disease: epidemiology, clinical aspects and treatment.

Authors:  Greetje J Tack; Wieke H M Verbeek; Marco W J Schreurs; Chris J J Mulder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-03-09       Impact factor: 46.802

3.  [Ten fractures in 21 years].

Authors:  J Fritzsch; G Hennicke; A Tannapfel
Journal:  Unfallchirurg       Date:  2005-11       Impact factor: 1.000

4.  The prevalence of celiac disease in children and adolescents in Germany.

Authors:  Martin W Laass; Roma Schmitz; Holm H Uhlig; Klaus-Peter Zimmer; Michael Thamm; Sibylle Koletzko
Journal:  Dtsch Arztebl Int       Date:  2015-08-17       Impact factor: 5.594

Review 5.  Celiac disease in children and adolescents: special considerations.

Authors:  Kimberly P Newton; Shereen A Singer
Journal:  Semin Immunopathol       Date:  2012-05-02       Impact factor: 9.623

6.  Prevalence of celiac disease in Germany: a prospective follow-up study.

Authors:  Wolfgang Kratzer; Monika Kibele; Atilla Akinli; Marc Porzner; Bernhard O Boehm; Wolfgang Koenig; Suemeyra Oeztuerk; Richard A Mason; Ren Mao; Mark H Haenle
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

7.  [Prevalence of an association between coeliac disease and vitiligo].

Authors:  J Henker; A Hartmann
Journal:  Hautarzt       Date:  2019-12       Impact factor: 0.751

Review 8.  Survey on computer aided decision support for diagnosis of celiac disease.

Authors:  Sebastian Hegenbart; Andreas Uhl; Andreas Vécsei
Journal:  Comput Biol Med       Date:  2015-02-23       Impact factor: 4.589

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.